Scaling Back Domestic Caprolactam Production and Limiting Volatility in Business Profit and Loss
First written in FY2024. 6 of 7 entries say "Advanced", first in FY2025. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Measures to reform the business structure are progressing, including bringing forward the scale-down or shutdown of manufacturing facilities in Thailand by one year for completion by March 2026, while scheduling the scale-down or shutdown of manufacturing facilities in Japan for March 2027 and March 2028.」
The initiative progressed beyond consideration of reducing domestic caprolactam production, with the scale-down or shutdown of ammonia, caprolactam and nylon polymer facilities in Thailand brought forward and completed, and shutdown timing in Japan also established. - FY2025AdvancedAnnual report
「In addition, the Company decided to scale down or shut down manufacturing facilities in Japan and Thailand for ammonia, caprolactam and nylon polymer, which have large fluctuations in earnings and high greenhouse gas (GHG) emissions.」
The scope expanded from considering a reduction in domestic caprolactam production to deciding to scale down or shut down ammonia, caprolactam and nylon polymer manufacturing facilities in Japan and Thailand. - FY2024First statedAnnual report
「The Company proceeded with customer-related measures aimed at reducing domestic caprolactam production in fiscal 2024.」
For the caprolactam and ammonium sulfate businesses, the Company disclosed plans to reduce domestic production in fiscal 2024 and reduce exposure to market fluctuations by optimizing its production structure in Japan and Thailand.